Travere Therapeutics Inc (TVTX) financials
Travere Therapeutics revenue and earnings by year
Travere Therapeutics's revenue was $491 million in the fiscal year to December 31, 2025, up 110.5% from the year before. Net income was -$25.5 million, -5.2% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 15.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 491 | 233 | 145 | 109 | 132 | 198 | 175 | 164 | 155 | 134 |
| Revenue growth | 110.5% | 60.5% | 32.7% | -17.0% | -33.5% | 13.1% | 6.8% | 6.0% | 16.0% | — |
| Gross profit | 480 | 225 | 134 | 105 | 128 | 192 | 170 | 159 | 151 | 129 |
| Gross margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% | 97.0% | 96.6% | 97.7% | 96.6% |
| Operating income | -63 | -324 | -388 | -320 | -199 | -173 | -107 | -68 | -34 | -40 |
| Operating margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -87.0% | -61.2% | -41.7% | -22.2% | -29.8% |
| Net income | -26 | -322 | -111 | -278 | -180 | -169 | -146 | -103 | -60 | -48 |
| Net margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% | -38.6% | -35.9% |
| Diluted EPS | -$0.29 | -$4.08 | -$1.61 | -$4.37 | -$3.01 | -$3.56 | — | -$2.54 | -$1.67 | — |
| Free cash flow | -20 | -274 | -322 | -215 | -39 | -67 | -74 | -45 | -7 | -15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TVTX in Markets.
How Travere Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| FILSPARI | $141M | 83.2% |
| Tiopronin Products | $20.3M | 12.0% |
| License | $8.23M | 4.9% |
See also: TVTX returns
No forecast, no recommendation. This page describes Travere Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.